Silence Therapeutics (SLN) Non-Current Deferred Tax Liability (2018 - 2020)

Silence Therapeutics has disclosed Non-Current Deferred Tax Liability across 3 years of filings, most recently posting $33011.3 for Q4 2020.

• Non-Current Deferred Tax Liability for Q4 2020 came in at $33011.3, up 6.98% year-over-year; the trailing twelve-month figure through Dec 2020 was $33011.3 (up 6.98% YoY), and the FY2020 annual result was $32103.7, up 4.76% from the prior year.
• Non-Current Deferred Tax Liability came in at $33011.3 for Q4 2020 at Silence Therapeutics, up from $30857.4 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $33011.3 in Q4 2020 to a low of $16728.0 in Q4 2018.
• The 3-year median for Non-Current Deferred Tax Liability is $30857.4 (2019), against an average of $26865.5.
• Across the five-year window, Non-Current Deferred Tax Liability surged 84.47% in 2019 and climbed 6.98% in 2020, its largest moves.
• Silence Therapeutics' Non-Current Deferred Tax Liability stood at $16728.0 in 2018, then jumped by 84.47% to $30857.4 in 2019, then gained by 6.98% to $33011.3 in 2020.
• The last three Non-Current Deferred Tax Liability figures came in at $33011.3 (Q4 2020), $30857.4 (Q4 2019), and $16728.0 (Q4 2018), per Business Quant data.